NCT01654484 - A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Glaucoma and Ocular Hypertension

Interventions

DRUG

DE-117

Ophthalmic Solution, QD, 28 Days

DRUG

0.0015% tafluprost

Ophthalmic Solution, QD, 28 days

DRUG

DE-117 and 0.0015% tafluprost

Ophthalmic Solutions, QD, 28 days

DRUG

Placebo

Ophthalmic Solution, QD, 28 days

Trial Locations (10)

14618

Santen Investigational Site, Rochester

30076

Santen Investigational Site, Roswell

30260

Santen Investigational Site, Morrow

33064

Santen Investigational Site, Deerfield Beach

33773

Santen Investigational Site, Largo

44115

Santen Investigational Site, Cleveland

76102

Santen Investigational Site, Fort Worth

78240

Santen Investigational Site, San Antonio

78731

Santen Investigational Site, Austin

92663

Santen Investigational Site, Newport Beach

All Listed Sponsors

lead

Santen Inc.

INDUSTRY